Search

The article informs that MModal Inc. has released its financial results for the three and six months ended June 30, 2012 along with corporate highlights. It indicates that total revenue for the three months in 2012 was 116.0 million U.S. dollars compared with 108.4 million U.S. dollars for the same period of 2010. While total revenue for the six months in 2012 was 233.4 million U.S. dollars compared with 219.7 million U.S. dollars in the previous year.

The article informs that BioScrip Inc. has released its financial results for the second quarter and full year (FY) ended June 30, 2012 along with corporate highlights. It indicates that total revenue from continuing operations for the second quarter has increased 24.3 million U.S. dollars compared to 2011. While gross profit from continuing operations was 53.0 million U.S. dollars compared to 51.8 million U.S. dollars in the previous year.

The article informs that Seattle Genetics Inc. has released its financial results for the second quarter and full year (FY) ended June 30, 2012 along with corporate highlights. It indicates that total revenue for the second quarter in 2012 was 48.8 million U.S. dollars compared with 13.1 million U.S. dollars for the same period of 2011. While total costs and expenses for the FY in 2012 were 66.1 million U.S. dollars compared with 64.8 million U.S. dollars in the previous year.

The article informs that CardioNet Inc. has released its financial results for the second quarter and full year (FY) ended June 30, 2012 along with corporate highlights. It indicates that total revenue for the second quarter in 2012 was 27.4 million U.S. dollars compared with 31.6 million U.S. dollars for the same period of 2011. While gross profit for the FY in 2012 decreased to 16.7 million U.S. dollars compared with 18.6 million U.S. dollars in the previous year.

The article provides information on the financial results of Ligand Pharmaceuticals Inc. for the second quarter ended June 30, 2012. It indicates that total revenue for the second quarter of 2012 was 5.7 million U.S. dollars compared to 7.5 million dollars in same period during 2011. The company also reported operating costs and expenses of 7.5 million dollars in the second quarter of 2012 compared to 8.7 million dollars in the second quarter of 2011.

The article provides information on the financial results of PhotoMedex Inc. for the second quarter and six months ended June 30, 2012. It indicates that total revenue for the second quarter of 2012 was 58.9 million U.S. dollars and gross profit for the second quarter was 46.5 million dollars. The company also reported net income of 4.2 million dollars in the second quarter of 2012 and 109.2 million dollars in revenues for the six months ended June 30, 2012.

The article provides information on the financial results of Cardiovascular Systems Inc. for the fourth quarter and full year 2012. It indicates that total revenue for the second quarter of 2012 was 22.9 million U.S. dollars compared to 21.7 million dollars in same period during 2011. The company also reported net loss of 16.8 million dollars for the fiscal year 2012 and revenues of 82.5 million dollars.

The article provides information on the financial results of Salix Pharmaceuticals Ltd. for the second quarter ended June 30, 2012. It indicates that total revenue for the second quarter of 2012 was 181 million U.S. dollars compared to 133.2 million dollars in same period during 2011. The company also reported cash and cash equivalents of 715.9 million dollars as of June 30, 2012.

The article provides information on the financial results of Accretive Health Inc. for the second quarter ended June 30, 2012. It indicates that net service revenue for the second quarter of 2012 was 236.7 million U.S. dollars. The company also reported a net loss of 0.6 million dollars compared with net income of 8.6 million dollars in the second quarter of 2011. The company will host a conference call on August 8, 2012 to discuss its financial results.

The article provides information on the financial results of Spectrum Pharmaceuticals Inc. for the second quarter and six months ended June 30, 2012. The company reported consolidated revenue of 68.7 million U.S. dollars for the second quarter of 2012. The company also reported GAAP net income of 18.1 million dollars in the second quarter of 2012 and non-GAAP net income of 23.5 million dollars.

The article provides information on the financial results of Columbia Laboratories Inc. for the second quarter and six months ended June 30, 2012. It indicates that total revenue for the second quarter of 2012 was 7.4 million U.S. dollars compared to 4.9 million dollars in the same period during 2011. The company also reported net income of 1.9 million dollars for the second quarter of 2012 and operating income of 1.7 million dollars.

The article provides information on the financial results of BioClinica Inc. for the second quarter and six months ended June 30, 2012. It indicates that service revenue for the second quarter of 2012 was 19.1 million U.S. dollars compared to 16.9 million dollars in same period during 2011. The company also reported GAAP net income of one million dollars in the second quarter of 2012 and non-GAAP net income of 1.4 million dollars.

The article provides information on the financial results of EpiCept Corp. for the second quarter and six months ended June 30, 2012. The total revenue for the second quarter of 2012 was 6.6 million U.S. dollars compared to 0.2 million dollars in same period during 2011. The research and development (R&D) expenses were one million dollars in the second quarter of 2012 compared to two million dollars in 2011. The company will also host a conference call on August 8, 2012.

The article provides information on the financial results of Seattle Genetics Inc. for the second quarter ended June 30, 2012. It indicates that total revenue for the second quarter of 2012 was 48.8 million U.S. dollars compared to 13.1 million dollars in same period during 2011. The company also reported total costs and expenses for the second quarter of 2012 were 66.1 compared to 64.8 million dollars for the second quarter of 2011.

The article provides information on the financial results of BioScrip Inc. for the second quarter ended June 30, 2012. It indicates that revenue from continuing operations for the second quarter of 2012 was 155.9 million U.S. dollars and net loss for the quarter was 4.3 million dollars. The company also reported consolidated adjusted EBITDA of nine million dollars for the second quarter of 2012.

The article provides information on the financial results of Metropolitan Health Networks Inc. for the second quarter and six months ended June 30, 2012. The company reported total revenue of 193.4 million U.S. dollars for the second quarter of 2012 compared to 97.3 million dollars in the same period during 2011. The gross profit was 28.4 million dollars in the second quarter of 2012 compared to 16.6 million dollars for the same quarter in 2011.

The article provides information on the consolidated financial results of Theragenics Corp. for the second quarter and six months ended June 30, 2012. The company reported consolidated revenue of 22 million U.S. dollars for the second quarter of 2012 and 43.5 million dollars for the first half of 2012. The company also reported consolidated earnings per share of 0.02 dollar in the second quarter of 2012 and 0.05 dollar for the first half of 2012.

The article provides information on the financial results of Idera Pharmaceuticals Inc. for the second quarter ended June 30, 2012. The company reported cash and cash equivalents of 13.2 million U.S. dollars for the second quarter of 2012 compared to 24.6 million dollars for the same period in 2011. Research & development (R&D) expenses for the second quarter of 2012 totaled 3.5 million dollars compared to 4.1 million dollars for the same period in 2011.

The article provides information on the financial results of U.S. Physical Therapy Inc. for the second quarter and six months ended June 30, 2012. The company's net income for the six months ended June 30, 2012 increased 7.9 percent to 9.3 million U.S. dollars from 8.6 million dollars for the same period during 2011. The net revenue for the first half of 2012 was 116,653,000 dollars and the net revenue for the second quarter of 2012 was 63,959,000 dollars.

The article provides information on the financial results of the company American Shared Hospital Services for the second quarter and first half of 2012. The revenue for the second quarter ended June 30, 2012 increased 1.9 percent to 4,284,000 U.S. dollars compared to 4,206,000 dollars for the same period during 2011. The net income was 15,000 dollars for the second quarter of 2012. For the six months ended June 30, 2012, the revenue was 8,687,000 dollars.

The article provides information on the financial results of CytRx Corp. for the three months and six months ended June 30, 2012. The Company reported no revenue for the second quarter of 2012. It reported net loss of13.3 million U.S. dollars for the quarter ended June 30, 2012 compared to 3.1 million dollars in same period during 2011. The company also reported research and development (R&D) expenses of 2.7 million dollars for the second quarter of 2012.

The article provides information on the financial and operating results of Medical Properties Trust Inc. for the second quarter ended June 30, 2012. It indicates that total revenues increased 46 percent for the second quarter of 2012 and normalized funds from operations per share increased 37 percent compared to the second quarter of 2011. The company will also hold a conference call and a webcast on August 9, 2012 to discuss its financial results.

The article focuses on the financial reports of the pharmaceuticals manufacturer Anacor Pharmaceuticals for the second quarter of the year 2012. It informs that clinical trials on the drug tavaborole in onychomycosis are giving desired results in the treatment process. It also informs that revenue of the company in the quarter was 2.6 million U.S. dollars.

The article focuses on the financial results of the company Codexis for second quarter of the year 2012. It informs that Codexis is the developer of processes for the production of biofuels, bio-based chemicals, and pharmaceuticals and the company reported revenues of 22.9 million U.S. dollars, a 12 percent decrease from 26.1 million dollars in the second quarter of the year 2011.

The article focuses on the financial results of the health care firm Kips Bay Medical Inc. It informs that Kips Bay Medical filed an application for an Investigational Device Exemption (IDE) with the U.S. Food & Drug Administration (FDA) and net sales of the company has been increased by 18.8 percent to 57,000 U.S. dollars in the second quarter of the year 2012.

The article focuses on the financial results released by the therapeutics manufacturer Celldex Therapeutics Inc. It informs that revenue of the company has decreased to 78.7 million U.S. dollars from March 31, 2012 is due to planned, increased operational expenses during the quarter related to ongoing studies of the drug rindopepimut.

The article presents information on the financial results of the company Medgenics Inc. It informs that the company has developed a novel technology for the sustained production of proteins of medicinal importance in patients using their own tissue so the sale of the company has increased to 1.64 million U.S. dollars.

The article offers information on the release of financial results by Conmed Healthcare Management Inc. for second quarter ended June 30, 2012. The revenues generated by the company increased by18 percent with total of 19.7 million dollars. The company earned operating income of 0.7 million dollars with gross profit of 3.6 million dollars.

The article offers information on the release of financial results by 3Pea International Inc. for second quarter ended June 30, 2012. The revenues generated by the company increased by 383 percent with total of 2,549,003 dollars. The company earned operating income of 360,468 dollars with an increase of 477 percent at 0.04 per basic and diluted share.

The article offers information on the release of financial results by Bioanalytical Systems Inc. for third quarter of 2012. The revenues generated by the company decreased to 7,186,000 dollars with gross margin of 28.7 percent. Operating expenses of the company in third quarter decreased to 1,976,000 dollars in comparison to 2,784,000 dollars for second quarter.

The article informs about the financial statement of AxoGen Inc. for the second quarter of the fiscal year 2012. It reported an increase in its business revenue from 1.23 million U.S. dollars to 1.51 million U.S. dollars. It gross profit has increased to about 89 percent. It mentions that its sales and marketing expenses have increased to 1.58 million U.S. dollars from 0.95 million U.S. dollars reported during the last year.

The article informs about the financial statement of Guided Therapeutics Inc. for the quarter and six month ending June 30, 2012. It reported an increase in its business revenue from 913,000 U.S. dollars to 915,000 U.S. dollars. Its net loss has been 1.2 million U.S. dollars. Its cash in hand at June 30, 2012 has been 1.4 million U.S. dollars as compared to one million U.S. dollars at March 31, 2012.

The article informs about the financial statement of ADMA Biologics Inc. for the second quarter ending June 30, 2012. It business revenue increased to 0.2 million U.S. dollars as compared to the same period in 2011. It has reported its research and development costs of 0.2 million U.S. dollars. Its operating expenses amounted to 0.4 million U.S. for the second quarter ending June 30, 2012 and 2011.

The article informs that BioLineRx Ltd. has released its financial results for the second quarter ended June 30, 2012 along with corporate highlights. It indicates that the sales and marketing expense for the second quarter of 2012 was 0.2 million U.S. dollars and operating loss was reported to be 5.1 million U.S. dollars. The financial income was reported to be 1.5 million U.S. dollars with a net loss of 2.9 million U.S. dollars.

The article discusses the 2012 2nd quarter financial performance of the company M*Modal to be discussed in a conference call and webcast held on August 8, 2012. It informs that the business revenue of the company for 2nd quarter of 2012 was 116 million U.S. dollars which showed an increase of 6.9 percent as compared with 108.4 million U.S. dollars for the 2nd quarter of 2011. It further informs about net income of the company for the 2nd quarter of 2012 which was 3 million U.S. dollars.

The article discusses 2012 2nd quarter financial performance of BioScrip Inc. It informs that business revenue of the company from continuing operations for the 2nd quarter of 2012 was 155.9 million U.S. dollars as compared to 131.6 million U.S. dollars for 2nd quarter of 2011. It further informs about the consolidated gross profit for the 2nd quarter of 2012 which was 53 million U.S. dollars.

The article offers information on the 2012 2nd quarter financial performance of Seattle Genetics Inc. to be discussed in a conference call and web cast held on August 8, 2012. It also informs that the business revenue of the company for 2012 2nd quarter was 48.8 million U.S. dollars as compared with 13.1 million U.S. dollars of 2nd quarter results of 2011. It further informs about net loss for the 2nd quarter of 2012 which was 17.2 million U.S. dollars.

The article offers information on the 2012 2nd quarter financial performance of CardioNet Inc. to be discussed in a conference call and web cast held on August 8, 2012. It also informs that the business revenue of the company for 2012 2nd quarter was 27.4 million U.S. dollars as compared with 31.6 million U.S. dollars of 2nd quarter results of 2011. It further informs about gross profit for the 2nd quarter of 2012 which was 16.7 million U.S. dollars.

The article offers information on the 2012 2nd quarter financial performance of Ligand Pharmaceuticals Inc. to be discussed in a conference call held on August 8, 2012. It also informs that the business revenue of the company for 2012 2nd quarter was 5.7 million U.S. dollars as compared with 7.5 million U.S. dollars of 2nd quarter results of 2011. It further informs about net loss for the 2nd quarter of 2012 which was 0.9 million U.S. dollars.

The article offers information on the 2012 2nd quarter financial performance of PhotoMedex Inc. It also informs that the business revenue of the company for 2012 2nd quarter which was 58.9 million U.S. dollars and showed an increase of 74 percent as compared with 2nd quarter results of 2011. It further informs about net income for the 2nd quarter of 2012 which was 4.2 million U.S. dollars.

The article discusses the 2012 fourth- quarter and full-year financial performance of Cardiovascular Systems Inc. to be discussed in a teleconference and web cast held on August 8, 2012. It also informs about the business revenue of the company for fourth quarter which was 22.9 million U.S. dollars. It further informs about the anticipation of the company for the fiscal 2013 1st quarter financial performance.

The article discusses the 2012 2nd quarter financial performance of Salix Pharmaceuticals Ltd. to be discussed in a conference call held on August 8, 2012. It also informs that live web cast of the conference call will be available on the company's website. It further informs about the product revenue of the company which was 181 million U.S. dollars for the 2nd quarter of 2012.

The article presents information on the financial results of Accretive Health Inc. for the second quarter of fiscal year 2012. The company reported services revenues of 236.7 million U.S. dollars for the second quarter of 2012 compared to 183.6 million U.S. dollars in the second quarter of 2011. Adjusted EBITDA for the second quarter of 2012 was 7.3 million U.S. dollars.

The article presents information on the financial results of Spectrum Pharmaceuticals Inc. for the second quarter of fiscal year 2012. The company reported consolidated revenue of 68.7 million U.S. dollars for the second quarter of 2012 compared to 45.4 million U.S. dollars in the second quarter of 2011. Net income for the second quarter of 2012 was 18.1 million U.S. dollars.

The article presents information on the financial results of Columbia Laboratories Inc. for the second quarter of fiscal year 2012. The company reported revenues of 7.4 million U.S. dollars for the second quarter of 2012 compared to 4.9 million U.S. dollars in the second quarter of 2011. Net income for the second quarter of 2012 was 1.9 million U.S. dollars.

The article presents information on the financial results of Seattle Genetics Inc. for the second quarter of fiscal year 2012. The company reported revenues of 48.8 million U.S. dollars for the second quarter of 2012 compared to 13.1 million U.S. dollars in the second quarter of 2011. Net loss for the second quarter of 2012 was 17.2 million U.S. dollars.

The article presents information on the financial results of BioScrip Inc. for the second quarter of fiscal year 2012. The company reported revenue from continuing operations as 155.9 million U.S. dollars for second quarter ended June 30, 2012. Net loss from continuing operations was reported as 4.3 million U.S. dollars.

The article presents information on the financial results of Pacira Pharmaceuticals Inc. for the second quarter of fiscal year 2012. Exparel sales totaled 2.3 million U.S. dollars in the second quarter ended June 30, 2012. Total revenues for the quarter ended June 30 2012 were 12.3 million U.S. dollars.

The article presents information on the financial results of Metropolitan Health Networks Inc. for the second quarter of fiscal year 2012. Revenue of 193.4 million U.S. dollars was recorded for the second quarter of 2012 compared to 97.3 million U.S. dollars in 2011. Net income of 2.9 million U.S. dollars was recorded for the second quarter of 2012 compared to 5.9 million U.S. dollars in 2011.

The article presents information on the financial results of Theragenics Corp. for the second quarter and first half of the fiscal year 2012. Consolidated revenue recorded as 22 million U.S. dollars for the second quarter of 2012, increased by two percent over 2011. Adjusted EBITDA recorded as 3.7 million U.S. dollars in the second quarter of 2012 compared to four million U.S. dollars in 2011.